Biotech Values

[DewDiligence]

FDA advisory committee endorses Takeda's Vedolizumab for Crohn’s and UC:

http://finance.yahoo.com/news/fda-advisory-committee-recommends-approval-010900701.html

Vedolizumab’s MoA, as decribed in Takeda’s PR:

Vedolizumab…is a humanized monoclonal antibody that specifically antagonizes the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1). MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha4beta7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha4beta7, vedolizumab may limit the ability of certain lymphocytes to infiltrate gut tissues.

This will be a crowded market, but a new MoA gives Vedolizumab a chance t be at least a medium-sized drug.